keyword
MENU ▼
Read by QxMD icon Read
search

Metabolic syndrome antipsychotic

keyword
https://www.readbyqxmd.com/read/28980344/association-between-antipsychotic-treatment-and-leptin-levels-across-multiple-psychiatric-populations-an-updated-meta-analysis
#1
Renee-Marie Ragguett, Margaret Hahn, Giovanni Messina, Sergio Chieffi, Marcellino Monda, Vincenzo De Luca
OBJECTIVE: Antipsychotics (APs) are associated with metabolic syndrome, with increases in leptin proposed as an underlying mechanism of AP-induced weight gain. Currently available meta-analyses on this topic have limited their populations of interest to those diagnosed with schizophrenia. The purpose of this meta-analysis is to explore the relationship between leptin levels and AP use across multiple psychiatric diagnoses, and also in healthy controls. METHOD: Systematic electronic searches were conducted using PubMed and OVID: Medline...
October 5, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28969353/the-link-between-the-immune-system-environment-and-psychosis
#2
Rajiv Radhakrishnan, Muzaffer Kaser, Sinan Guloksuz
The last decade has witnessed a burgeoning interest in studies exploring the link between psychosis spectrum disorders (PSD) and altered immune function. While epidemiological and clinical studies point to evidence for increased peripheral inflammatory markers in PSD, it is not clear whether peripheral inflammation correlates with central inflammation in the brain. Furthermore, these studies are confounded by multiple methodological and disorder-related factors such as antipsychotic medications, smoking, obesity, and metabolic syndrome, all of which independently contribute to altered inflammation...
July 1, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28931411/topiramate-s-effectiveness-on-weight-reduction-in-overweight-obese-persons-with-schizophrenia-study-protocol-for-a-randomized-controlled-trial
#3
Miyuru Chandradasa, Layani Champika, Silumini de Silva, K A L A Kuruppuarachchi
BACKGROUND: Schizophrenia is a psychiatric disorder with a higher mortality than that of the general population. Most of the deaths are due to cardiovascular causes and are related to metabolic risks. This risk is due not only to antipsychotics but also to inherent factors of the disorder. Studies in the West have shown topiramate to be effective in schizophrenia to reduce weight gain and for symptomatic control. Whether this is effective for South Asians is not known. It is important because South Asians have a higher risk of metabolic syndrome...
September 20, 2017: Trials
https://www.readbyqxmd.com/read/28927969/comparison-of-metabolic-syndrome-prevalence-in-patients-with-schizophrenia-and-bipolar-i-disorder
#4
Razieh Nayerifard, Majid Akbari Bureng, Alireza Zahiroddin, Massood Namjoo, Sepideh Rajezi
Research has shown that the metabolic syndrome is more prevalent among patients with schizophrenia or bipolar I disorder. Given the scarcity of research on the disorders, this paper aims to compare the prevalence of the syndrome among the two groups of patients. METHODS: A total of 120 individuals participated in this cross sectional study: 60 patients with schizophrenia (26 males and 34 females) and 60 patients with bipolar I disorder (32 males and 28 females). The psychological disorders were diagnosed by some experienced psychiatrists according to the DSM-V...
May 4, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28915908/advances-in-paediatrics-in-2016-current-practices-and-challenges-in-allergy-autoimmune-diseases-cardiology-endocrinology-gastroenterology-infectious-diseases-neonatology-nephrology-neurology-nutrition-pulmonology
#5
REVIEW
Carlo Caffarelli, Francesca Santamaria, Dora Di Mauro, Carla Mastrorilli, Silvia Montella, Sergio Bernasconi
This review reports main progresses in various pediatric issues published in Italian Journal of Pediatrics and in international journals in 2016. New insights in clinical features or complications of several disorders may be useful for our better understanding. They comprise severe asthma, changing features of lupus erythematosus from birth to adolescence, celiac disease, functional gastrointestinal disorders, Moebius syndrome, recurrent pneumonia. Risk factors for congenital heart defects, Kawasaki disease have been widely investigated...
September 16, 2017: Italian Journal of Pediatrics
https://www.readbyqxmd.com/read/28879574/genetic-variants-impacting-metabolic-outcomes-among-people-on-clozapine-a-systematic-review-and-meta-analysis
#6
REVIEW
Rachel J Suetani, Dan Siskind, Heidi Reichhold, Steve Kisely
Clozapine is the gold standard medication for treatment refractory schizophrenia, but unfortunately, its use is also associated with many adverse metabolic side effects. There may be a strong genetic component to the development of these adverse effects. We undertook a systematic review to examine the evidence for genetic variation being associated with secondary metabolic outcomes in patients with schizophrenia on clozapine, under both longitudinal and cross-sectional study designs. We limited studies to those examining patients definitely taking clozapine, unlike prior reviews that have examined metabolic effects of patients taking a range of antipsychotic medications...
September 6, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28860773/can-melatonin-prevent-or-improve-metabolic-side-effects-during-antipsychotic-treatments
#7
Maria-Cristina Porfirio, Juliana Paula Gomes de Almeida, Maddalena Stornelli, Silvia Giovinazzo, Diane Purper-Ouakil, Gabriele Masi
In the last two decades, second-generation antipsychotics (SGAs) were more frequently used than typical antipsychotics for treating both psychotic and nonpsychotic psychiatric disorders in both children and adolescents, because of their lower risk of adverse neurological effects, that is, extrapyramidal symptoms. Recent studies have pointed out their effect on weight gain and increased visceral adiposity as they induce metabolic syndrome. Patients receiving SGAs often need to be treated with other substances to counteract metabolic side effects...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28827873/prevalence-and-predictors-of-metabolic-syndrome-in-schizophrenia-patients-from-assam
#8
Dulmoni Das, Kaustubh Bora, Banti Baruah, Gitumoni Konwar
BACKGROUND: Metabolic abnormalities contribute enormously to morbidity and mortality in schizophrenia. OBJECTIVES: Our objectives were to determine the (i) prevalence of metabolic syndrome (MS); and (ii) predictors for MS in schizophrenia patients from Assam. MATERIALS AND METHODS: Seventy-five schizophrenia patients were evaluated for MS. Risk factors were assessed by odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Fifty-nine patients (78...
April 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28818421/erbb-signaling-antagonist-ameliorates-behavioral-deficit-induced-by-phencyclidine-pcp-in-mice-without-affecting-metabolic-syndrome-markers
#9
Hagar Tadmor, Idit Golani, Ravid Doron, Ilana Kremer, Alon Shamir
Schizophrenia is a severe syndrome that affects about 1% of the world population. Since the mid-1950s, antipsychotics have been used to treat schizophrenia with preference for treating positive symptoms; however, their tolerance level is low, there are numerous side effects, and only some patients respond to the treatment. Antipsychotic medications that are more effective, better tolerated, and with fewer adverse effects are urgently needed. Given the accumulating evidence of the role filled by the ErbB signaling network in the biology of the dopamine, GABA, and glutamate systems, and in the etiology of schizophrenia, we hypothesized that the ErbB network is a candidate for development of a novel agent through which various symptoms of schizophrenia and other psychiatric disorders might be treated...
August 14, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28816926/feasibility-and-relevance-of-antipsychotic-safety-monitoring-in-children-with-tourette-syndrome-a-prospective-longitudinal-study
#10
Tamara Pringsheim, Josephine Ho, Justyna R Sarna, Tracy Hammer, Scott Patten
PURPOSE/BACKGROUND: Antipsychotics are efficacious for tics and are increasingly prescribed to children with behavioral disorders. Antipsychotics have important adverse effects, and systematic monitoring of drug safety is infrequently performed. The objectives of this study were to determine the feasibility of antipsychotic safety monitoring in children with Tourette Syndrome using a defined protocol and to evaluate the risk of adverse effects with chronic use. METHODS/PROCEDURES: A prospective longitudinal study of children prescribed antipsychotics was performed...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28808933/cardiovascular-disease-in-clozapine-treated-patients-evidence-mechanisms-and-management
#11
REVIEW
Kathlyn J Ronaldson
Myocarditis occurs in about 3% of those initiated on clozapine but monitoring reduces the risk of serious outcome. Cardiomyopathy may develop after myocarditis, or from prolonged tachycardia. Monitoring using echocardiography is not deemed cost effective. Tachycardia, orthostatic hypotension and reduced heart rate variability are a group of clozapine-related adverse effects associated with autonomic dysfunction and may have serious consequences in the long term. Elevated heart rate and poor heart rate variability can be treated with a β-blocker or a non-dihydropyridine calcium channel blocker, while orthostatic hypotension can be alleviated by increased fluid intake and abdominal binding, but may require pharmacological intervention...
August 14, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28796022/a-pilot-study-of-the-usefulness-of-a-single-olanzapine-plasma-concentration-as-an-indicator-of-early-drug-effect-in-a-small-sample-of-first-episode-psychosis-patients
#12
Arantzazu Zabala, Mariana Bustillo, Imanol Querejeta, Marta Alonso, Oiane Mentxaka, Ana González-Pinto, Amaia Ugarte, J Javier Meana, Miguel Gutiérrez, Rafael Segarra
PURPOSE/BACKGROUND: Studies analyzing concentration-effect relationships in second-generation antipsychotics have reported contradictory results in chronic schizophrenia. No data are available for the early stages of the disease. The present study aims to evaluate the association between a single olanzapine plasma concentration, clinical response, and severity of adverse effects in first-episode psychosis (FEP); to test the utility of various plasma breakpoints as markers of early response to treatment; and to identify variables affecting olanzapine concentrations...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28783382/development-of-metabolic-syndrome-in-drug-naive-adolescents-after-12-months-of-second-generation-antipsychotic-treatment
#13
Christina Power Sjo, Anne Dorte Stenstrøm, Anders Bo Bojesen, Jacob Stampe Frølich, Niels Bilenberg
OBJECTIVES: Mental illness is often accompanied by poor physical health and shorter life expectancy. Second-generation antipsychotics (SGAs) are suspected of increasing cardiovascular risk, possibly through development of metabolic syndrome (MetS), and the risk of adverse outcome is even higher if obesity or metabolic aberration starts in childhood or adolescence. METHODS: Drug-naive adolescents were recruited after contact with an outpatient Psychosis Team. Changes relative to baseline in body mass index (BMI), waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), triglycerides (TG), and high-density lipoprotein (HDL) cholesterol were determined through regular follow-ups...
August 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28764912/c-reactive-protein-and-cardiovascular-risk-in-bipolar-disorder-patients-a-systematic-review
#14
REVIEW
Victoria S Marshe, Shamira Pira, Outi Mantere, Bert Bosche, Karl J Looper, Nathan Herrmann, Daniel J Müller, Soham Rej
OBJECTIVES: New research is revealing a strong association between inflammatory markers with bipolar disorder (BD), potentially due to the high prevalence of cardiovascular disease and cardiovascular risk factors in BD. We aimed to synthesize the literature examining the association between the clinically most relevant inflammatory marker, C-reactive protein (CRP) and cardiovascular disease and cardiovascular risk factors in patients with BD. METHODS: MEDLINE, Embase and PsychInfo were systematically searched for all relevant English language articles published prior to April 2017...
October 3, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28764273/prevalence-of-metabolic-syndrome-among-psychiatric-inpatients-a-hospital-based-study-from-kashmir
#15
Tajamul Hussain, Mushtaq Ahmad Margoob, Sheikh Shoib, Mahak Shafat, Rajesh Kumar Chandel
INTRODUCTION: Over the last fifty years there has been dramatic change in the human environment, behaviours and way-of-life. These changes have resulted in escalating rates of metabolic syndrome not only in general population but also among people with mental illness. Various factors, like the lack of exercise, use of psychotropic medications and inadequate medical care leads to the increased risk of metabolic changes among people with mental illness. Hence, there is a greater need to evaluate metabolic syndrome in this population...
June 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28750582/efficacy-and-safety-of-min-101-a-12-week-randomized-double-blind-placebo-controlled-trial-of-a-new-drug-in-development-for-the-treatment-of-negative-symptoms-in-schizophrenia
#16
Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Elisabeth Luthringer, Sandra Werner, Joseph Reilly, Jean-Yves Schaffhauser, Jonathan Rabinowitz, Mark Weiser, Remy Luthringer
OBJECTIVE: The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia. METHOD: The trial enrolled 244 patients who had been symptomatically stable for at least 3 months and had scores of at least 20 on the negative subscale of the Positive and Negative Syndrome Scale (PANSS)...
July 28, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28719155/antipsychotic-treatment-is-associated-with-inflammatory-and-metabolic-biomarkers-alterations-among-first-episode-psychosis-patients-a-7-month-follow-up-study
#17
Roman Balõtšev, Liina Haring, Kati Koido, Vambola Leping, Kärt Kriisa, Mihkel Zilmer, Veiko Vasar, Anneli Piir, Aavo Lang, Eero Vasar
AIM: Second-generation antipsychotics are commonly used to treat schizophrenia, but may cause metabolic syndrome (MetS) in a subset of patients. The mechanisms of antipsychotic-related metabolic changes remain to be established, especially in first-episode psychosis (FEP) patients. METHODS: In the present study, we used a chip technology to measure metabolic (C-peptide, insulin, leptin, adiponectin and resistin) and inflammatory biomarkers (ferritin, interleukin-6, interleukin-1α, tumour necrosis factor-α and plasminogen activator inhibitor-1) in the serum samples of a population of FEP patients before and after 7 months of antipsychotic drug treatment, compared to control subjects (CS)...
July 18, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28718688/effect-of-adjunctive-ranitidine-for-antipsychotic-induced-weight-gain-a-systematic-review-of-randomized-placebo-controlled-trials
#18
Xiao-Jing Gu, Rui Chen, Chen-Hui Sun, Wei Zheng, Xin-Hu Yang, Shi-Bin Wang, Gabor S Ungvari, Chee H Ng, Andrei Golenkov, Grace K I Lok, Lu Li, Ines H I Chow, Fei Wang, Yu-Tao Xiang
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. The primary outcome measures were body mass index (BMI) (kg/m(2)) and body weight (kg). Four RCTs with five study arms were identified and analyzed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28688350/changes-in-the-cytokine-profile-in-first-episode-drug-na%C3%A3-ve-patients-with-psychosis-after-short-term-antipsychotic-treatment
#19
Petros Petrikis, Paraskevi V Voulgari, Alexandros T Tzallas, Vassiliki A Boumba, Dimitra T Archimandriti, Dimitrios Zambetas, Ioannis Papadopoulos, Ioannis Tsoulos, Petros Skapinakis, Venetsanos Mavreas
An increasing body of evidence suggests that antipsychotic medication can cause immunological changes that could be attributed to the amelioration of psychotic symptoms or the metabolic side effects of the drugs. So far, the results of the studies remain controversial. Our aim was to compare the levels of interleukin (IL) IL-2, IL-6 and transforming growth factor-β2 (TGF-β2) in drug-naïve, first-episode patients with psychosis before and after six weeks of antipsychotic medication. Thirty-nine first-episode patients with psychosis were enrolled in the study...
October 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28672735/safety-concerns-associated-with-second-generation-antipsychotic-long-acting-injection-treatment-a-systematic-update
#20
Salvatore Gentile
Background It has been recently suggested that second-generation antipsychotic long-acting injection (SGA-LAIs) are underutilized in clinical practice, despite that their costs significantly impact on national health system budgets. Hence, an updated analysis of safety data shown by SGA-LAIs may contribute to clarify their role in clinical practice. Materials and methods English-language, peer-reviewed articles reporting updated, primary findings on the SGA-LAI safety were identified (updated through an electronic search of five databases - PubMed, EMBASE, PsycInfo, DARE and the Cochrane Library)...
June 23, 2017: Hormone Molecular Biology and Clinical Investigation
keyword
keyword
73394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"